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The multidimensional impact of chronic skin diseases on
the individual and their family unit has been, until recently,
under-appreciated, and measurement has proved difficult
because of its essentially subjective nature. Health-Related
Quality of Life (HRQoL) measures were devised as an at-
tempt to provide standardized quantitative data and a more
meaningful and structured approach to patient care. Used
together with physical measures of eczema severity, they
can help to provide a more holistic approach to disease
management and are perceived as a positive indication of
the physician’s interest by the patient/family, helping to es-
tablish good rapport. It is to be hoped that the resultant
improved patient/physician relationship may prove benefi-
cial to treatment concordance and disease management
(Carroll et al, 2005).
It is generally agreed that HRQoL measures should in-
clude items on physical, psychological, and social function-
ing and well-being, but frequently the content of domains
are poorly specified (Eiser et al, 2001a). There are many
variables to consider, which include age, gender, education,
social class, ethnicity, and the respondent’s own psycho-
logical affect. Many scales lack precision regarding the
content of domains of HRQoL, and most may not be cul-
turally appropriate for all ethnic groups (Eiser et al, 2001a). A
compromise has to be struck between scales that include
many items that may be more able to capture maximum
data in a research setting, versus scales with fewer items
providing less data, but with the advantage of ease of use in
a clinical setting. When investigating HRQoL it is essential to
use existing questionnaires proven to be valid and reliable
as a gold standard, and devising new ones should be
avoided unless it can be shown that this provides extra and
relevant data. Where new questionnaires are deemed es-
sential, they should be validated (for construction, content,
and criterion) and determined to be reliable (intra- and inter-
observer reliability and internal consistency). No single
scale is likely to be ideal for all circumstances, and it is often
useful to include a range of previously validated question-
naires. These could include a generic HRQoL, a measure of
psychological stress and anxiety and a gold standard for
the specific speciality or target disease, as well as the par-
ticular scale under development, and they should be ap-
propriate for the age and ethnicity of the target population.
An important consideration when investigating HRQoL in
children is the use of proxy measures, usually completed by
the parent(s) or other caregiver. These are necessary for
younger children or those with cognitive difficulties and can
be used alongside child-reported indices for school-aged
children. It should be recognized, however, that parental
and child views on the impact of disease may vary, partic-
ularly in the case of subjective emotions such as sadness or
embarrassment, although there is greater agreement over
physical disability (Eiser et al, 2001b). Although many stud-
ies have shown that HRQoL impact increases with disease
severity, it is important to remember that this relationship is
not necessarily a linear one, but is dependent upon various
factors, including body site and a person’s coping ability.
The rising incidence of atopic dermatitis in industrialized
countries throws a large burden onto the family group, so-
ciety, and health care resources. Some attempt has been
made to measure the psychosocial and financial impact. Su
et al (1997) used a generic questionnaire for determining the
effect of chronic disease on parent and families. This ap-
proach allowed direct comparison of families of children
with eczema to those with other chronic diseases, such as
diabetes and asthma. They concluded that families with
moderate to severe eczema had a significantly higher im-
pact on family score than families of diabetic children, and
the financial cost of managing eczema both to the com-
munity and families was higher than managing asthma.
Use of the dermatology-specific Children’s Dermatology
Quality of Life Index (CDLQI) has demonstrated that eczema
and other itchy dermatoses have a greater overall impact on
HRQoL than other common chronic diseases, such as acne
or psoriasis in school-age children (Lewis-Jones and Finlay,
1995). This 10-item measure for school-age children pro-
vides a simple, rapid scale for everyday clinical use, but the
small number of items may account for lower scores in
diseases that have a large psychological impact but exhibit
fewer clinical symptoms. Many studies, including our own,
have found that children with eczema report itching, sleep
loss, and problems at school as the most frequent and im-
portant items. A recent study in our department comparing
the child versus parent’s perspective in eczema showed
reasonably good agreement.1 Use of the Infant’s Dermatitis
Quality of Life index (IDQoL) demonstrated that infants with
eczema also have the greatest problems with itching, sleep
loss, mood, and behavioral changes (Lewis-Jones et al,
2001). Other reported problems were discomfort with treat-
1Beattie and Lewis-Jones: Brit J Dermatol, accepted for
publication.
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ment and difficulties with playing, bathing, dressing, and at
meal times.
In a family study of eczema we used in-depth ethno-
graphic interviews and brainstorming sessions to provide
qualitative data for construction of the 10-question Derma-
titis Family Index (DFI), and demonstrated a large psycho-
social impact on families of children up to age 12 y (Lawson
et al, 1998). Eleven problem areas were identified, of which
the practical difficulties of caring for a child with atopic ec-
zema (skin care, feeding, shopping, washing, and cleaning),
psychological pressures, physical exhaustion, and restric-
tion of family lifestyle were the areas of highest impact.
Other areas of life impact included sleep disturbance, fi-
nancial, recreational, and family relationships. Financial
pressures were rated as relatively unimportant for the ma-
jority of families (health care is free for children in the UK)
but a minority, all single parent families, faced great financial
hardship because of their child’s eczema. Parents rated the
child being able to cope with their eczema as being of par-
amount importance. Balkrishnan et al (2003) used a mod-
ified version of the DFI for use in the USA and demonstrated
that the parent/caregiver’s perception of clinical severity
was the most significant predictor of impact of eczema on
the family. The CDLQI, IDQoL, and DFI are validated and
proven as reliable in many languages. Sensitivity to clinical
change has been demonstrated and quantified for the
CDLQI and DFI (Ben-Gashir et al, 2002, 2004), making them
useful for clinical studies and outpatient audit purposes.2
The disadvantage of the brevity of these three measures is
the relative lack of information they provide on the specific
life domains affected, but they are useful for flagging prob-
lem areas for further exploration where appropriate.
In a study from Germany using several established
measures, Warschburger et al (2004) examined the psy-
chological adjustment in parents of young children with ec-
zema and the impact on their quality of life. They found high
rates of psychological stress, levels of which were directly
related to the severity of the child’s eczema. McKenna et al
(2005) recently published on the further development of the
PIQoL-AD in several European countries. This 28-item scale
measures the impact of eczema in families of young chil-
dren and has promising validity, but has yet to be compared
to other similar measures. They highlight the psychological
impact of eczema and confirm the level of physical ex-
haustion suffered by parents due to the child’s sleepless-
ness. In this issue, qualitative data from Chamlin et al (2005)
correspond well with the aforementioned and other family
studies. They describe the development and initial valida-
tion studies of the Childhood Atopic Dermatitis Impact
Score (CADIS). This novel measure for use by parents of
young American children less than 6 y of age combines a
proxy measure of the impact on the child (four subscales)
and the impact on the family (four subscales) in 45 ques-
tions. The approach of combining the proxy measure for the
child’s and the parents’ rating scale is, I think, an excellent
one. They highlight the huge psychological pressure for
parents, and it is a weakness, therefore, that they omitted
the use of other validated HRQoL scales or measures of
stress and anxiety as comparators, thus robbing them of
the opportunity to obtain valuable additional information
and validation. They are, however, not alone in this omis-
sion; use of comparative measures has been a failing of
many HRQoL studies, including some of our own work. As
the field of HRQoL expands, it is important that we use a
more structured epidemiological and comparative ap-
proach if it is to advance beyond ‘‘infancy.’’
Despite their shortcomings, HRQoL studies have done
much to identify the terrible burden that childhood eczema
places on the child and the family unit, which is currently
unrecognized by health care analysts. The high world prev-
alence of atopic eczema and the other atopic diseases
makes atopy one of the most important groups of all chron-
ic childhood diseases. Identification of both the financial
and psychosocial burden to individuals and society will en-
able us to argue for the appropriate necessary resources for
disease management in the future.
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